Boon, Paul http://orcid.org/0000-0002-4180-8896
Ferrao Santos, Susana http://orcid.org/0000-0001-6029-6235
Jansen, Anna C. http://orcid.org/0000-0002-3835-2824
Lagae, Lieven http://orcid.org/0000-0002-7118-0139
Legros, Benjamin http://orcid.org/0000-0002-9938-7457
Weckhuysen, Sarah http://orcid.org/0000-0003-2878-1147
Article History
Received: 24 July 2020
Accepted: 26 August 2020
First Online: 13 October 2020
Compliance with ethical standards
:
: P Boon has received speaker and consultancy grants from UCB, Medtronic and LivaNova and research grants from the same companies through Ghent University Hospital, outside the submitted work. S Ferrao Santos reports receiving a travel grant from UCB for participation in a medical congress, outside the submitted work. AC Jansen reports speaker honoraria and consultancy fees from Novartis and UCB, outside the submitted work. L Lagae reports grants from UCB, Eisai, Novartis, Zogenix and LivaNova, outside the submitted work; in addition, L Lagae has a patent "Fenfluramine in Dravet syndrome" with potential royalties paid through the University of Leuven. B Legros reports travel grants and speaker honoraria from UCB and speaker honoraria from LivaNova, outside the submitted work. S Weckhuysen reports speaker fees from Biocodex, UCB and Zogenix, and consultancy fees from Xenon and Zogenix, outside the submitted work.
: This article does not contain any studies with human participants or animals performed by any of the authors.
: For this type of study formal consent is not required.